Fig. 2
From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
ORR analysis for NIVO1/IPI3. Figure shows the ORR analysis in selected trials in which NIVO1/IPI3 schedule was administered. Fixed effect model—Heterogeneity not significant (P = 0.89). NIVO1/IPI3: nivolumab 1 mg/kg and ipilimumab 3 mg/kg